A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Hidetoshi HayashiShunichi SugawaraYasushi FukudaDaichi FujimotoSatoru MiuraKeiichi OtaYuichi OzawaSatoshi HaraJunko TanizakiKoichi AzumaShota OmoriMotoko TachiharaKazumi NishinoAkihiro BesshoYasutaka ChibaKoji HarataniKazuko SakaiKazuto NishioNobuyuki YamamotoKazuhiko NakagawaPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Nivolumab did not confer a longer PFS compared with carboplatin-pemetrexed in the study patients. Gene expression profiling identified some cases with a favorable tumor immune microenvironment that was associated with nivolumab efficacy.
Keyphrases
- small cell lung cancer
- phase ii study
- advanced non small cell lung cancer
- open label
- epidermal growth factor receptor
- end stage renal disease
- locally advanced
- brain metastases
- newly diagnosed
- genome wide
- ejection fraction
- chronic kidney disease
- tyrosine kinase
- stem cells
- peritoneal dialysis
- prognostic factors
- placebo controlled
- radiation therapy
- clinical trial
- randomized controlled trial
- transcription factor
- rectal cancer